

**Dated-17.01.2026**

**BSE LIMITED**

Corporate Relations Department  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort  
Mumbai-400001  
**Scrip code: 543264**

**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**

Listing Department  
Exchange Plaza, 5<sup>th</sup> Floor, Plot no. C/1  
G Block, Bandra Kurla Complex, Bandra (E)  
Mumbai-400051  
**Scrip Code: NURECA**

**Subject: Outcome of Board Meeting under Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

We wish to inform you that the Board of Directors of the Company at the meeting held today i.e. January 17, 2026 have:

1. Approved the unaudited standalone and consolidated Financial Results for the third quarter and nine months ended December 31, 2025.

Copies of unaudited standalone and consolidated Financial Results along with Limited Review Reports are enclosed herewith.

The Board Meeting commenced at 04:15 PM and concluded at 05:30 PM.

This is for your kind information and records please.

Thanking You,

Yours Sincerely,  
For **Nureca Limited**

**(Nishu Kansal)**  
**Company Secretary & Compliance Officer**  
**M. No. A33372**

**NURECA LIMITED**

Correspondence Office: SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh, India - 160002  
Registered Office: Andheri West B-205, Bldg -42, B wing, Dhanashree heights, Azad Nagar Sangam CHS,  
Andheri West, Mumbai – 400053  
Phone No. +91-172-5292900, CIN: L24304MH2016PLC320868

**NURECA LIMITED**

Andheri West B-205, Bldg -42, B wing, Dhanashree heights, Azad Nagar Sangam CHS, Andheri West, Mumbai – 400053  
 Tel: +91 -172-5292900, E-mail: [cs@nureca.com](mailto:cs@nureca.com), Website: [www.nureca.com](http://www.nureca.com)  
 Corporate Identification Number: L24304MH2016PLC320868

(Amount in INR million, unless otherwise stated)

**Statement of Unaudited Standalone Financial Results for the Quarter and Nine months ended 31 December 2025**

Sr. No.	Particulars	31 December 2025 (Unaudited)	Quarter ended 30 September 2025 (Unaudited)	31 December 2024 (Unaudited)	Nine months ended 31 December 2025 (Unaudited)	31 December 2024 (Unaudited)	Year ended 31 March 2025 (Audited)
1	Revenue from operations	396.40	378.41	272.08	1,118.05	828.90	1,146.40
2	Other income	22.85	23.81	15.18	72.58	105.42	125.40
3	<b>Total income (1+2)</b>	<b>419.25</b>	<b>402.22</b>	<b>287.26</b>	<b>1,190.63</b>	<b>934.32</b>	<b>1,271.80</b>
4	<b>Expenses</b>						
	Purchase of stock-in-trade	382.66	249.17	208.97	885.69	556.11	864.89
	Changes in inventories of stock-in-trade	(101.48)	9.52	(16.51)	(102.22)	33.82	(68.04)
	Employee benefits expense	38.99	37.94	36.00	117.71	103.74	143.56
	Finance costs	1.77	4.10	1.41	7.89	5.21	11.15
	Depreciation and amortization expense	4.55	4.82	4.93	14.16	16.78	21.53
	Other expenses	52.28	55.60	90.94	177.52	238.24	303.31
	<b>Total expenses</b>	<b>378.77</b>	<b>361.15</b>	<b>325.74</b>	<b>1,100.75</b>	<b>953.90</b>	<b>1,276.40</b>
5	<b>Profit / (Loss) before tax for the period (3-4)</b>	<b>40.48</b>	<b>41.07</b>	<b>(38.48)</b>	<b>89.88</b>	<b>(19.58)</b>	<b>(4.60)</b>
6	<b>Tax expense</b>						
	- Current tax	0.03	-	(2.88)	0.05	8.87	(11.98)
	- Current tax related to previous year	(0.34)			(0.34)		
	- Deferred tax	8.48	9.67	(2.71)	20.95	(1.05)	14.06
7	<b>Profit / (Loss) after tax for the period (5-6)</b>	<b>32.31</b>	<b>31.40</b>	<b>(32.89)</b>	<b>69.22</b>	<b>(27.40)</b>	<b>(6.70)</b>
8	<b>Other comprehensive income</b>						
A	(i) Item that will not be reclassified to profit or loss	-	-	0.13	-	0.40	0.52
	(ii) tax relating to items that will not be reclassified to profit or loss	-	-	(0.03)	-	(0.10)	(0.13)
B	(i) Item that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Other comprehensive income for the period (net of tax)</b>	<b>-</b>	<b>-</b>	<b>0.10</b>	<b>-</b>	<b>0.30</b>	<b>0.39</b>
9	<b>Total comprehensive income/(loss) for the period (7+8)</b>	<b>32.31</b>	<b>31.40</b>	<b>(32.79)</b>	<b>69.22</b>	<b>(27.11)</b>	<b>(6.31)</b>
10	<b>Paid-up equity share capital (Refer note 4)</b> (Face value of share - Rs.10 each)	95.42	100.00	100.00	95.42	100.00	100.00
11	<b>Other equity</b>						1,824.79
12	<b>Earning per share of Rs. 10 each</b> - Basic and diluted (in rupees) (not annualized)	<b>3.39</b>	<b>3.14</b>	<b>(3.29)</b>	<b>7.25</b>	<b>(2.74)</b>	<b>(0.67)</b>

**Notes to the Unaudited standalone financial results:**

- These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards (IND AS) as notified by Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standard) Rules, 2015, as amended and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other accounting principles generally accepted in India.
- The Company operates in single business segment i.e. "Home healthcare and wellness products" hence there are no reportable segments as per Ind AS 108 "Operating Segments".
- During the previous quarter, the Company has filed Scheme of Merger by Absorption wherein and whereby Nureca Technologies Private Limited, a wholly owned subsidiary of the Company will be merged with the Company ("the Scheme of Merger"). The Scheme of Merger is effective from a proposed appointed date of April 1, 2025, subject to the sanction of the National Company Law Tribunal and other regulatory approvals. Pending sanction of the Scheme of Merger, no accounting impact has been recognized in these interim results.
- Pursuant to the approval of the shareholders and in accordance with the provisions of the Companies Act, 2013 and the SEBI (Buy-Back of Securities) Regulations, 2018, Nureca Limited undertook a buyback of equity shares through the tender offer route during the period. The Company bought back equity shares at a price of ₹330 per share for an aggregate consideration not exceeding ₹19.14 crore. The buyback was funded from the Company's free reserves, including securities premium. The record date for determining eligible shareholders was December 12, 2025 and The buyback was completed during the quarter ended December 31, 2025 accordingly equity shares bought back have been extinguished in accordance with applicable law, and a Capital Redemption Reserve equal to the nominal value of the shares bought back has been created pursuant to Section 69 of the Companies Act, 2013.
- During the period, the Government of India notified the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 ("Labour Codes"). The Company has evaluated the impact of the Labour Codes on its employee benefit obligations. The incremental estimated impact of Rs. 1.5 millions has been recognised under "Employee Benefit Expenses" in these interim results.
- The above standalone results have been reviewed by the Audit committee and approved by the Board of Directors at their meetings held on 17 January 2026 respectively. The statutory auditors have carried out a Limited Review of the results for the quarter and half year ended 31 December 2025.

For and on behalf of Board of Directors of  
**Nureca Limited**

**Saurabh Goyal**

Place: Chandigarh  
 Date: 17 January 2026

(Managing Director)  
 DIN : 00136037

**NURECA LIMITED**

Andheri West B-205, Bldg -42, B wing, Dhanashree heights, Azad Nagar Sangam CHS, Andheri West, Mumbai – 400053  
Tel: +91 -172-5292900, E-mail: [cs@nureca.com](mailto:cs@nureca.com), Website: [www.nureca.com](http://www.nureca.com)  
Corporate Identification Number: L24304MH2016PLC320868

*(Amount in INR million, unless otherwise stated)*

Statement of Unaudited Consolidated Financial Results for the Quarter and Nine Months ended 31 December 2025							
Sr. No	Particulars	Quarter ended		Nine Months ended		Year ended	
		31 December 2025 (Unaudited)	30 September 2025 (Unaudited)	31 December 2024 (Unaudited)	31 December 2025 (Unaudited)	31 December 2024 (Unaudited)	31 March 2025 (Audited)
1	Revenue from operations	396.42	377.40	264.63	1,115.58	779.21	1,096.61
2	Other income	21.90	23.18	14.77	70.79	104.42	124.35
3	<b>Total income (1+2)</b>	<b>418.32</b>	<b>400.58</b>	<b>279.40</b>	<b>1,186.37</b>	<b>883.63</b>	<b>1,220.96</b>
4	<b>Expenses</b>						
	Cost of material consumed	103.44	57.63	39.95	201.89	74.36	112.91
	Purchase of stock-in-trade	248.62	170.21	143.15	608.12	385.17	636.76
	Changes in inventories of work in progress, finished goods and stock-in-trade	(99.61)	10.28	(17.79)	(97.66)	30.88	(69.55)
	Employee benefits expense	43.17	41.65	38.44	129.33	110.37	153.07
	Finance costs	2.76	4.59	1.75	9.83	5.94	12.14
	Depreciation and amortization expense	5.00	5.37	5.40	15.69	18.16	23.38
	Other expenses	68.30	64.90	101.02	214.27	265.83	338.82
	<b>Total expenses</b>	<b>371.68</b>	<b>354.63</b>	<b>311.92</b>	<b>1,081.47</b>	<b>890.71</b>	<b>1,207.53</b>
5	<b>Profit / (Loss) before tax for the period (3-4)</b>	<b>46.64</b>	<b>45.95</b>	<b>(32.52)</b>	<b>104.90</b>	<b>(7.08)</b>	<b>13.43</b>
6	<b>Tax expense</b>						
	- Current tax	1.45	0.38	(1.99)	2.65	11.17	(8.17)
	- Current tax related to previous year	(0.25)	-	-	(0.25)	-	-
	- Deferred tax	8.10	9.31	(2.52)	20.77	(2.04)	13.14
7	<b>Profit/ (loss) after tax for the period from continuing operations (5-6)</b>	<b>37.34</b>	<b>36.26</b>	<b>(28.01)</b>	<b>81.73</b>	<b>(16.21)</b>	<b>8.46</b>
8	<b>Profit before tax from discontinued operations</b>	-	0.02	-	0.02	-	-
9	<b>Tax expense of discontinued operations</b>	-	-	-	-	-	-
10	<b>Profit for the period from discontinued operations (8-9)</b>	<b>0.00</b>	<b>0.02</b>	<b>0.00</b>	<b>0.02</b>	<b>0.00</b>	<b>0.00</b>
11	<b>Other comprehensive income</b>						
A	(i) Item that will not be reclassified to profit or loss	-	-	0.13	-	0.40	4.43
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	(0.03)	-	(0.10)	(1.07)
B	(i) Item that will be reclassified to profit or loss	-	-	-	-	-	(0.08)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	(0.06)	-	(0.08)	-
	<b>Total other comprehensive income for the period (net of tax)</b>	<b>-</b>	<b>-</b>	<b>0.04</b>	<b>-</b>	<b>0.22</b>	<b>3.28</b>
10	<b>Paid-up equity share capital (Refer note 4) (Face value of share - Rs.10 each)</b>	<b>100.00</b>	<b>100.00</b>	<b>100.00</b>	<b>100.00</b>	<b>100.00</b>	<b>100.00</b>
11	<b>Other equity</b>						<b>1,842.85</b>
12	<b>Earning/(loss) per share of Rs. 10 each</b>						
	<b>For Continuing operations</b>						
	- Basic and diluted (in rupees) (not annualized)	3.91	3.63	(2.80)	8.56	(1.62)	0.89
	<b>For Discontinued operations</b>						
	- Basic and diluted (in rupees) (not annualized)	-	0.00	-	0.00	-	-
	<b>For Continuing &amp; Discontinued operations</b>	<b>3.91</b>	<b>3.63</b>	<b>(2.80)</b>	<b>8.56</b>	<b>(1.62)</b>	<b>0.89</b>
	- Basic and diluted (in rupees) (not annualized)						

**Notes to the Unaudited consolidated financial results:**

- These Consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards (IND AS) as notified by Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act 2013 read with the Companies (Indian Accounting Standard) Rules, 2015, as amended and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other accounting principles generally accepted in India.
- The Company operates in single business segment i.e. "Home healthcare and wellness products" hence there are no reportable segments as per Ind AS 108 "Operating Segments".
- During the previous quarter, the Company has filed Scheme of Merger by Absorption wherein and whereby Nureca Technologies Private Limited, a wholly owned subsidiary of the Company will be merged with the Company ("the Scheme of Merger"). The Scheme of Merger is effective from a proposed appointed date of April 1, 2025, subject to the sanction of the National Company Law Tribunal and other regulatory approvals. There is no impact is required to be recognised as wholly owned subsidiary is being merged with the parent Company.
- Pursuant to the approval of the shareholders and in accordance with the provisions of the Companies Act, 2013 and the SEBI (Buy-Back of Securities) Regulations, 2018, the holding company undertook a buyback of equity shares through the tender offer route during the period. The holding company bought back equity shares at a price of ₹330 per share for an aggregate consideration not exceeding ₹19.14 crore. The buyback was funded from the holding company's free reserves, including securities premium. The record date for determining eligible shareholders was December 12, 2025 and the buyback was completed during the quarter ended December 31, 2025 accordingly equity shares bought back have been extinguished in accordance with applicable law, and a Capital Redemption Reserve equal to the nominal value of the shares bought back has been created pursuant to Section 69 of the Companies Act, 2013.
- During the period, the Government of India notified the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 ("Labour Codes"). The Company has evaluated the impact of the Labour Codes on its employee benefit obligations. The incremental estimated impact of Rs. 1.5 millions has been recognised under "Employee Benefit Expenses" in these interim results.
- The above Consolidated results have been reviewed by the Audit committee and approved by the Board of Directors at their meetings held on 17 January 2026 respectively. The statutory auditors have carried out a Limited Review of the results for the quarter and half year ended 31 December 2025.

For and on behalf of Board of Directors of  
**Nureca Limited**

Place: Chandioarh  
Date: 17 January 2026

**Saurabh Goyal**  
(Managing Director)  
DIN : 00136037



**Independent Auditor's Review Report on Standalone Unaudited Financial Results for the quarter and nine months ended December 31, 2025 Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended**

To the Board of Directors of Nureca Limited

1. We have reviewed the accompanying statement of unaudited financial results of Nureca Limited (the "Company") for the quarter and nine months ended December 31, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results read with notes therein, prepared in all material respects in accordance with the applicable accounting standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



5. The Statement includes unaudited Standalone Financial Results of the Company for the quarter and nine months ended December 31, 2024 and audited results for year ended March 31, 2025, which were reviewed / audited by erstwhile auditors whose review / audit report dated January 24, 2025, and May 5, 2025 respectively, expressed an unmodified conclusion / opinion on the said Results.

For Singhi & Co.

Chartered Accountants

Firm Registration No. 302049E



Place: Noida (Delhi – NCR)

Date: January 17, 2026

  
Bimal Kumar Sipani

Partner

Membership No. 088926

UDIN : 26088926UXRZEN6313

**Independent Auditor's Review Report on Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2025 Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended**

To Board of Directors of Nureca Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Nureca Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and nine months ended December 31, 2025, ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities as mentioned below :
  - a. Nureca Limited – Holding Company (incorporated in India)
  - b. Nureca Technologies Private Limited – Subsidiary (incorporated in India)
  - c. Nureca Healthcare Private Limited – Subsidiary (incorporated in India)\* (till September 11, 2025)
  - d. Nureca INC – Subsidiary (incorporated in USA)

\* strike-off during the period.





5. Based on our review conducted and procedures performed as stated in paragraph 3 above, except for the possible effect of the matter described in para 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement read with notes therein, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The accompanying Statement includes the financial results and other financial information which we did not review, in respect of:
- One subsidiary, whose interim financial results reflects total revenues of Rs. 134.03 millions and Rs. 277.34 millions, total net profit after tax of Rs. 7.07 millions and Rs. 15.62 millions and total comprehensive income of Rs. 7.07 millions and Rs. 15.62 millions, for the quarter and nine months ended December 31, 2025 respectively as considered in the Statement. This interim financial information have been reviewed by other auditor whose report has been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.
  - One subsidiary which was strike-off during the period, whose interim financial results include total revenues of Rs. Nil and Rs. 0.05 millions, total net profit after tax of Rs. Nil and Rs. 0.02 millions and total comprehensive income of Rs. Nil and Rs. 0.02 millions, for the quarter and for the period April 1, 2025 to September 11, 2025 respectively as considered in the Statement, which have been prepared by management of the subsidiary and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of the subsidiary is based solely on the management prepared financial statements. In our opinion and according to the information and explanations given to us by the Board of Directors, these financial results are not material to the Group.
  - A foreign subsidiary, whose interim financial results include total revenue from operation of Rs. Nil and Rs. Nil, net profit/(loss) after tax of Rs. (0.05) millions and Rs. (0.29) millions and total comprehensive income of Rs. (0.05) millions and Rs. (0.29) millions for the quarter and nine months ended December 31, 2025, respectively, as considered in the Statement which have been not been reviewed by its auditor. These financial results have been prepared by its management as per applicable accounting standards of its country of incorporation and the Parent Company's management converted the financial results of the subsidiary located outside India from accounting

principles generally accepted in the country of incorporation to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Parent Company's management. In our opinion and according to the information and explanations given to us by the Board of Directors, these financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of matters stated above.

7. The Statement includes unaudited Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2024 and audited results for the year ended March 31, 2025, which were reviewed / audited by erstwhile auditors whose review / audit report dated January 24, 2025, and May 5, 2025 respectively, expressed an unmodified conclusion / opinion on the said Results.

Place: Noida (Delhi – NCR)

Date: January 17, 2026



For Singhi & Co.

Chartered Accountants

Firm Registration No. 302049E

  
Bimal Kumar Sipani

Partner

Membership No. 088926

UDIN : 26080926PT09QH5547